Navigation Links
Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
Date:10/29/2010

was directed to all three Orange Book listed patents for INTUNIV. ADDITIONAL INFORMATION The following additional information is included in this press release: Page Overview of Q3 2010 Financial Results 8 Financial Information 12 Notes to Editors 25 Safe Harbor Statement 25 Explanation of Non GAAP Measures 26 Trademarks 27

Dial in details for the live conference call for investors 14:00 BST/9:00 EDT on October 29, 2010:

UK dial in: 0844-335-0351 US dial in: 1-866-8048688 or 1-718-3541175 International dial in: +44-844-335-0351 Password/Conf ID: 921510 Live Webcast: http://www.shire.com/shireplc/en/investors OVERVIEW OF Q3 2010 FINANCIAL RESULTS 1. Product sales

For the three months to September 30, 2010 product sales increased by 32% to $794.3 million (2009: $602.5 million) and represented 91% of total revenues (2009: 90%).

Core Product Sales increased by 31% to $694.6 million (2009: $531.6 million), up 34% on a CER basis. Product Highlights

Exit Market Growth Share(1) Product Sales $M Sales CER US Rx(1) VYVANSE 151.2 +17% 1 +17% +28% 15% ELAPRASE 96.8 +7% 1 +11% n/a(2) n/a(2) REPLAGAL 92.1 +91% 1 +103% n/a(3) n/a(3) LIALDA / MEZAVANT 76.0 +16% 1 +17% +16% 19% PENTASA 57.1 +11% +11% -5% 15% VPRIV 49.5 n/a 1 n/a n/a(2) n/a(2) FOSRENOL 45.2 -5% 1 -1% -17% 7% INTUNIV 37.3 n/a 1 n/a n/a 3% FIRAZYR 2.9 +61% 1 +73% n/a(3) n/a(3) OTHER 86.5 -11% 1 -8% n/a n/a Core product sales 694.6 +31% 1 +34% ADDERALL XR 99.7 +41% 1 +40% +1% 7% Total product sales 794.3 +32% 1 +35%

(1) Data provided by IMS Health National Prescription Audit ("IMS NPA"). Exit market share represents the average monthly US market share in the month ended September 30, 2010.

(2) IMS NPA Data not available.

(3) Not sold in the US in Q3 2010.

VYVANSE - ADHD

The increase in VYVANSE product sales was princi
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
2. Reportlinker Adds Shire plc: PharmaVitae Profile
3. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
4. Shire plc - Statement re ProAmatine
5. Shire Proposes to Expand Specialist Gastrointestinal Portfolio
6. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
7. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
8. Shire plc Appoints Two New Board Directors
9. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
10. Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
11. INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... R-Biopharm ... quantification of partially hydrolyzed gluten in foods, has been accepted by AOAC International ... “Partially Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” based on ...
(Date:7/30/2015)... July 30, 2015 AACC welcomed thousands ... 2015 AACC Annual Meeting & Clinical Lab Expo ... 26–30. The meeting showcased revolutionary advancements in clinical ... of healthcare providers to diagnose patients quickly and ... treatment. As of Wednesday, July ...
(Date:7/30/2015)... ... July 30, 2015 , ... Tronics, ... as Sales & Marketing Director. , With more than 25 years of ... for reinforcing Tronics’ business development activities worldwide. He brings to the company his ...
(Date:7/30/2015)... VANCOUVER, Washington , July 30, 2015 ... "Biosimulation Market, by Product (Software, Molecular Modeling, PB/PK, PKPD, ... (Drug Discovery & Development, Preclinical, Clinical Trial), by End ... the Biosimulation Market is expected to reach USD 2,107.99 ... at a CAGR of 15.29%. Browse ...
Breaking Biology Technology:RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Tronics appoints Francois Vieillard as Sales and Marketing Director 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4
... palm plantations will worsen the dual environmental crises of ... protected, warn scientists in the most comprehensive review of ... from the Zoological Society of London and University of ... the role of palm oil production in tropical deforestation ...
... Micromet, Inc.,(Nasdaq: MITI ) ("Micromet" or ... for the treatment of cancer,inflammation and autoimmune diseases, ... board of directors appointed Dr. Peter Johann, a,current ... member of the Company,s,audit committee. The appointment fills ...
... 15 Inverness Medical,Innovations, Inc. (Amex: IMA ), ... solutions, today declared a,dividend of $4.77 per share on ... dividend will be paid in shares of Series B,stock ... of (a) $4.77 divided by,(b) 97% of the average ...
Cached Biology Technology:Oil palm plantations are no substitute for tropical rainforests, a new study shows 2Oil palm plantations are no substitute for tropical rainforests, a new study shows 3Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule 2Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule 3Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule 4Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock 2
(Date:7/2/2015)... 25, 2015 Research ... of the "Natural Language Processing Market by ... OCR, Pattern & Image Recognition) - Worldwide Forecast ... The key vendors occupying the market are ... Microsoft Corporation, NetBase Solutions, SAS Institute Inc., Verint ...
(Date:6/30/2015)... NEW YORK , June 30, 2015 To ... biometric security provider HYPR Corp. announced today the addition of ... will serve as board advisor and David Raviv ... to the team underscore HYPR Corp.,s commitment to providing the ... , Dimitri Sirota co-founded Layer 7 Technologies, a ...
(Date:6/26/2015)... ATL Technology, LLC, a top provider of electromechanical contract manufacturing ... headquartered in Springville, Utah , has announced ... corporation with locations in Santa Clara, CA ... ). This acquisition will incorporate MedConx,s manufacturing facility ... existing facility in Costa Rica , resulting ...
Breaking Biology News(10 mins):Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2
... States stem from bat bites, far more people are treated ... most often reported rabid mammal. Controlling the spread of rabies ... where new outbreaks might occur and how the virus might ... journal PLoS Biology, Real and colleagues apply a mathematical model ...
... isn't very clear, especially when it comes to the vaccine ... end if you want to understand what the vaccine is ... 16, 2005 -- The European Vaccine Effort against HIV/AIDS today ... vaccines comprising DNA-HIV-C and NYVAC-HIV-C for the prevention of HIV ...
... Environmental Microbiology reveals that indigenous microbiota of the ... oil. Scientists from the Estación Experimental del Zaidín ... in situ crude oil degradation after the Prestige ... spill, hydrocarbons are subjected to physicochemical processes such ...
Cached Biology News:Rabies spread speeds up 2'EuroVacc 02' HIV Vaccine Trial Begins 2'EuroVacc 02' HIV Vaccine Trial Begins 3A hope for oil spill bioremediation 2
Mouse Wnt-9b Biotinylated Affinity Purified PAb ENTREZ GeneID: 22412...
Biotin anti-human CD164...
Mouse H60 Allophycocyanin MAb (Clone 205326) ENTREZ GeneID: 15101...
... Ready-to-use liquid controls for monitoring Aldolase ... & abnormal) with targeted manufacturing values ... 20 ± 3 IU/L. 30-day ... at 2-8 C. Level 1: 3 ...
Biology Products: